Effects of a sedative antihistamine, D-chlorpheniramine, on regional cerebral perfusion and performance during simulated car driving

Human Psychopharmacology

Volumn 23, Issue 2, 2008, Pages 139-150

  Tashiro, Manabu ^a,b   Sakurada, Yumiko ^a   Mochizuki, Hideki ^a   Horikawa, Etsuo ^a,c   Maruyama, Masahiro ^a   Okamura, Nobuyuki ^a   Watanuki, Shoichi ^b   Arai, Hiroyuki ^a   Itoh, Masatoshi ^b   Yanai, Kazuhiko ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

Antihistamine; Car driving; Cerebral blood flow; Impaired performance; PET

Indexed keywords

ANTIHISTAMINIC AGENT; DEXCHLORPHENIRAMINE; OXYGEN 15; PLACEBO;

ADULT; ARTICLE; ATTENTION DISTURBANCE; BRAIN BLOOD FLOW; BRAIN DYSFUNCTION; BRAIN PERFUSION; BRAIN REGION; CAR DRIVING; CEREBELLUM VERMIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN EXPERIMENT; MALE; MOTOR DYSFUNCTION; NORMAL HUMAN; ORBITAL CORTEX; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS MODEL; REST; RIGHT HANDEDNESS; SINGLE BLIND PROCEDURE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE; TEMPORAL LOBE; VIDEOTAPE; VISUAL CORTEX;

ADMINISTRATION, ORAL; ADULT; AUTOMOBILE DRIVING; BRAIN; CEREBROVASCULAR CIRCULATION; CHLORPHENIRAMINE; CROSS-OVER STUDIES; FUNCTIONAL LATERALITY; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOMOTOR PERFORMANCE; SPACE PERCEPTION; VIDEOTAPE RECORDING; VISUAL PERCEPTION;

EID: 40549123703     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.909     Document Type: Article

References (54)

1. Aso T, Sakai Y. 1988. Effects of terfenadine on actual driving performance. Jpn J Clin Pharmacol Ther 19: 681-688.
2. Brown RE, Stevens DR, Haas HL. 2001. The physiology of brain histamine. Prog Neurobiol 63: 637-672.
3. Calhoun VD, Carvalho K, Astur R, Pearlson GD. 2005. Using virtual reality to study alcohol intoxication effects on the neural correlates of simulated driving. Appl Psychophysiol Biofeedback 30: 285-306.
4. Calhoun VD, Pekar JJ, Mcginty VB, Adali T, Watson TD, Pearlson GD. 2002. Different activation dynamics in multiple neural systems during simulated driving. Hum Brain Mapp 16: 158-167.
5. Calhoun VD, Pekar JJ, Pearlson GD. 2004. Alcohol intoxication effects on simulated driving: exploring alcohol-dose effects on brain activation using functional MRI. Neuropsychopharmacology 29: 2097-2107.
6. Chapman LJ, Chapman JP. 1987. The measurement of handedness. Brain Cogn 6: 175-183.
7. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. 1995. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2: 189-210.
8. Gengo FM, Gabos C. 1987. Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 59: 53-57.
9. Hatta T, Kawakami A. 1995. Patterns of handedness in modern Japanese: a cohort effect shown by re-administration of the H.N. Handedness inventory after 20 years. Can J Exp Psychol 49: 505-512.
10. Hindmarch I. 1976. The effects of the sub-chronic administration of an anti-histamine, clemastine, on tests of car driving ability and psychomotor performance. Curr Med Res Opin 4: 197-206.
11. Hindmarch I, Bhatti JZ. 1987. Psychomotor effects of astemizole and chlorpheniramine, alone and in combination with alcohol. Int Clin Psychopharmacol 2: 117-119.
12. Hindmarch I, Hanks GW, Hewett AL 1977. Clobazam, a 1,5-benzodiazepine, and car-driving ability. Br J Clin Pharmacol 4: 573-578.
13. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. 1973. Quantification of sleepiness: a new approach. Psychophysiology 10: 431-436.
14. Holgate ST, Canonica GW, Simons FE, et al. 2003. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 33: 1305-1324.
15. Horikawa E, Okamura N, Tashiro M, et al. 2005. The neural correlates of driving performance identified using positron emission tomography. Brain Cogn 58: 166-171.
16. Jeong M, Tashiro M, Singh LN, et al. 2006. Functional brain mapping of actual car-driving using [18F]FDG-PET. Ann Nucl Med 20: 623-628.
17. Jueptner M, Weiller C. 1998. A review of differences between basal ganglia and cerebellar control of movements as revealed by functional imaging studies. Brain 121: 1437-1449.
18. Koelega HS. 1995. Alcohol and vigilance performance: a review. Psychopharmacology (Berl) 118: 233-249.
19. Mochizuki H, Tashiro M, Tagawa M, et al. 2002. The effects of a sedative antihistamine, D-chlorpheniramine, on visuomotor spatial discrimination and regional brain activity as measured by positron emission tomography (PET). Hum Psychopharmacol 17: 413-418.
20. Movig KL, Mathijssen MP, Nagel PH, et al. 2004. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 36: 631-636.
21. Nicholson AN, Pascoe PA, Turner C, et al. 1991. Sedation and histamine HI-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 104: 270-276.
22. Okamura N, Yanai K, Higuchi M, et al. 2000. Functional neuroimaging of cognition impaired by a classical antihistamine, D-chlorpheniramine. Br J Pharmacol 129: 115-123.
23. Oldfield RC. 1971. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9: 97-113.
24. Peets EA, Jackson M, Symchowicz S. 1972. Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 180: 364-374.
25. Qidwai JC, Watson GS, Weiler JM. 2002. Sedation, cognition, and antihistamines. Curr Allergy Asthma Rep 2: 216-222.
26. Ramaekers G, Lamers J, Verhey F, et al. 2002. A comparative study of the effects of carbarnazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic. Psychopharmacology (Berl) 159: 203-210.
27. Ramaekers JG, O'Hanlon JF. 1994. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 47: 261-266.
28. Ramaekers JG, Uiterwijk MM, O'Hanlon JF. 1992. Effects of loratadine and cetirizine on actual driving and psychometric test perfornnance, and EEG during driving. Eur J Clin Pharmacol 42: 363-369.
29. RedBook, 1998. Medical Economics, p 609, Montvale, NJ.
30. Ridout F, Hindmarch I. 2001. Effects of tianeptine and mianserin on car driving skills. Psychopharmacology (Berl) 154: 356-361.
31. Ridout F, Meadows R, Johnsen S, Hindmarch I. 2003a. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 18: 261-269.
32. Ridout F, Shamsi Z, Meadows R, Johnson S, Hindmarch I, 2003b. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180Mg alone and with alcohol, with hydroxyzine hydrochloride 50Mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 25: 1518-1538.
33. Sabatowski R, Schwalen S, Rettig K, Herberg KW, Kasper SM, Radbruch L. 2003. Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manage 25: 38-47.
34. Seppala T, Linnoila M, Mattila MJ. 1979. Drugs, alcohol and driving. Drugs 17: 389-408.
35. Starbuck VN, Kay GG, Platenberg RC, Lin CS, Zielinski BA. 2000. Functional magnetic resonance imaging reflects changes in brain functioning with sedation. Hum Psychopharmacol 15: 613-618.
36. Tagawa M, Kano M, Okamura N, et al. 2002. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. Br J Clin Pharmacol 53: 296-304.
37. Tagawa M, Kano M, Okamura N, et al. 2001. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol 52: 501-509.
38. Talairach J, Tournoux P. 1988. Co-Planar Stereotaxic Atlas of the Human Brain. Georg Thierne Verlag: Stuttgart, Germany.
39. Tashiro M, Horikawa E, Mochizuki H, et al. 2005. Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone use. Hum Psychopharmacol 20: 501-509.
40. Tashiro M, Mochizuki H, Iwabuchi K, et al. 2002. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 72: 409-414.
41. Tashiro M, Mochizuki H, Sakurada Y, et al. 2006. Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 61: 16-26.
42. Tashiro M, Sakurada Y, Iwabuchi K, et al. 2004. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 44: 890-900.
43. Theunissen EL, Vermeeren A, Van Oers AC, Van Maris I, Ramaekers JG. 2004. A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clin Exp Allergy 34: 250-258.
44. Uchiyama Y, Ebe K, Kozato A, Okada T, Sadato N. 2003. The neural substrates of driving at a safe distance: a functional MRI study. Neurosci Lett 352: 199-202.
45. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. 1995. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346: 667-670.
46. van Laar M, Volkerts; E, Verbaten M. 2001. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl) 154: 189-197.
47. Verster JC, De Weert AM, Bijtjes SI, et al. 2003. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 169: 84-90.
48. Verster JC, Volkerts ER. 2004. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 92: 294-303, Quiz 303-295, 355.
49. Walter H, Vetter SC, Grothe J, Wunderlich AP, Hahn S, Spitzer M. 2001. The neural correlates of driving. Neuroreport 12: 1763-1767.
50. Warrington SJ. 1991. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 6 (Suppl. 2): 11-21.
51. Weiler JM, Bloomfield JR, Woodworth GG, et al. 2000. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 132: 354-363.
52. Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T. 1999. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 29 (Suppl. 3): 29-36, discussion 37-28.
53. Yanai & Ryu JH, Watanabe T, et al. 1995. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 116: 1649-1655.
54. Yanai K, Tashiro M. 2007. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 113: 1-15.